Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates
Maura H. Parker(CTI BioPharma (United States)), Byoung Y. Ryu(CTI BioPharma (United States)), Ryan Larson(CTI BioPharma (United States)), Mollie M. McDonnell(University of Washington), Weiliang Tang(Chinese University of Hong Kong), Alissa Brandes(Unknown), Richard Manivanh, Yong Ha Youn(St. Jude Children's Research Hospital), Laurie Beitz(Seattle Children's Hospital), Hans‐Peter Kiem(Fred Hutch Cancer Center), Andrew M. Scharenberg(CTI BioPharma (Italy)), Nolan G. Ericson, Kristen Mittelsteadt(University of Washington), Chang‐Chih Wu(University of Tennessee Health Science Center), Justin Theophilus Ulrich-Lewis(CTI BioPharma (United States)), Seungjin Shin(Vector (United States)), Rebecca Gottschalk(Oxford Instruments (United Kingdom)), Eric J. Cavanaugh(Fred Hutch Cancer Center), A. Koo, Greyson Hamilton
Cited by 2
Related Papers
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
|New England Journal of Medicine|2006|902